[{"indications": "Indications\u00a0chronic hepatitis B infection with\r\ncompensated liver disease, evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis", "name": "TELBIVUDINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.3 Viral hepatitis", "5.3.3.1 Chronic hepatitis B"], "cautions": "Cautions\u00a0monitor liver function tests every 3\r\nmonths and viral markers of hepatitis B every 3\u20136 months during treatment\r\n(continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation); lamivudine-resistant chronic hepatitis B\u2014risk of telbivudine resistance; discontinue if deterioration in liver function, hepatic\r\nsteatosis, progressive hepatomegaly or unexplained lactic acidosis; interactions: Appendix 1 (telbivudine)Counselling\u00a0Patients should be advised\r\nto promptly report unexplained muscle pain, tenderness, or weakness,\r\nor numbness, tingling or burning sensations", "side-effects": "Side-effects\u00a0nausea, diarrhoea, abdominal pain, raised serum\r\namylase and lipase; cough; dizziness, headache, fatigue; rash; less commonly taste disturbance, arthralgia, myalgia, myopathy\r\n(discontinue treatment), and peripheral neuropathy; also reported,\r\nlactic acidosis and rhabdomyolysis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200281.htm", "doses": ["adult and child over 16 years, 600\u00a0mg once daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]